Figure 1.

Study design of the four trials. CR, complete response; PR, partial response; NC, no clinical response. EC-T, epirubicin, cyclophosphamide followed by docetaxel; FEC, 5-fluorouracil, epirubicin, cyclophosphamide; EC-P, epirubicin, cyclophosphamide followed by paclitaxel; AC-T, doxorubicin, cyclophosphamide followed by docetaxel; E-P, epirubicin followed by paclitaxel; AT, doxorubicin, docetaxel; TAC, docetaxel, doxorubicin, cyclophosphamide; NX, vinorelbine, capecitabine. q2W, every 2 weeks; q3W, every 3 weeks; q4W, every 4 weeks. i.v., intravenously; p.o., per orally; d, day.